Ascletis Pharma Inc. (ASCLF)
NEGATIVEFundamental
27
Precio
$9.88
Capitalización Bursátil
$10.11B
Parte 1 · Cuánto vale la empresa
Resumen
Ascletis Pharma is a Hangzhou-based Chinese biotech that develops and, on a small scale, sells drugs. It already markets treatments for hepatitis C, including Ganovo and a ritonavir tablet, in China, but that legacy business generates only minimal revenue. The company has pivoted most of its research toward metabolic disease — obesity and fatty liver — with pipeline candidates like ASC30 and ASC41, and it has also licensed in a China-market NASH drug, denifanstat, from a US partner.
Cómo genera ingresos
Ascletis earns a small amount of revenue selling its approved hepatitis C drugs in China, but this legacy business is not the point of the company today: most of the value investors are pricing in depends on drug candidates still in clinical trials that generate no revenue at all. Until a metabolic-disease drug such as ASC30 or ASC41 is approved and launched, Ascletis is funded mainly by capital raised from investors rather than by product sales.
Los argumentos a favor
Buyers argue that early obesity data — a Phase 2 US study reported 7.7% weight loss for its oral GLP-1 candidate — puts Ascletis in one of the most closely watched drug categories in the industry, and that its established, revenue-generating hepatitis C franchise shows the company can already get drugs through Chinese regulators and to market.
Los argumentos en contra
Sellers worry that Ascletis' actual product revenue is still minimal, that its valuation rests almost entirely on obesity and metabolic-disease candidates years away from approval in a field crowded with better-funded rivals, and that its pivot away from the older hepatitis C business leaves little near-term commercial base to fall back on.
Written by the editors, published on 18 de agosto de 2026
Direct competitors
Who this company fights with for the same customers
Generated on 23 de agosto de 2026 with claude-opus-5 — shared with all users
Viking's oral VK2735 tablet targets the same obesity patients with the same oral-pill format, making it the other emerging-biotech contender competing with ASC30 for prescriptions and for a partner or acquirer.
Lilly's orforglipron is the oral small molecule GLP-1 that Ascletis explicitly benchmarks ASC30 against on weight loss and tolerability, and its amylin agonist eloralintide competes head-on with Ascletis' ASC39.
Novo Nordisk defends the obesity market Ascletis is trying to enter, with oral semaglutide and the oral candidate amycretin aimed at exactly the same overweight and type 2 diabetes patients.
Both are clinical-stage biotechs whose entire value rests on a once-daily oral small molecule GLP-1 agonist for chronic weight management, with Structure's aleniglipron and Ascletis' ASC30 running competing global Phase III obesity programmes.
Hengrui's HRS-7535 is the Chinese oral small molecule GLP-1 furthest ahead in obesity and type 2 diabetes, competing with ASC30 both for Chinese patients and for out-licensing deals with Western partners.
Innovent's mazdutide is already the reference weight-loss therapy in China and is the incumbent ASC30 would have to displace in Ascletis' home market.
Balance y Liquidez
Ingresos
$2M
Últimos 12 meses hasta el último trimestre publicado — estimación a partir de métricas por acción
Beneficio Neto
$-387M
Últimos 12 meses hasta el último trimestre publicado — estimación a partir de métricas por acción
Flujo de Caja Libre
$-300M
Patrimonio Neto Total
$2.39B
Pasivo Total
$5M
Ratio de Liquidez
15.05
Cobertura de Intereses
-
Deuda/EBITDA
-
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$23.97
Precio Actual
$9.88
Margen de Seguridad
+58.8%
Rango de Valor Justo
$22.77 - $25.17
Métodos de Estimación
Métricas de Valoración
Ratio P/E
-
ROE
-18.5%
Ratio P/B
4.93
P/FCF
-
Margen Bruto
26.0%
ROIC
-20.8%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
-20.8%
WACC
8.0%
ROIC − WACC
-28.7 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (5)
- Price CAGR 5.62%
- Debt/Equity ratio
- Current Ratio
- Analyst Consensus 78% Buy
- Net Margin Trend -17745.6% vs -23455.7%
Fallido (9)
- ROIC -20.8%
- Gross Margin 26.0%
- P/B Ratio 4.93
- Operating Margin -17712.5%
- Positive Free Cash Flow
- DCF valuation (Unknown)
- ROE -18.9%
- Revenue Growth 5Y -43.4%
- Piotroski F-Score 0/9
No disponible (13)
- EPS data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- Earnings Surprise (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (missing shares data)
Piotroski F-Score
Preocupaciones financieras graves
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Dr. Jinzi Wu Ph.D. | Founder, Chairman & CEO | 62 |
| Ms. Hejingdao Wu | Senior VP of Operations & Executive Director | 51 |
| Dr. Kristjan Sigurdur Gudmundsson | Senior Consultant & Head of Discovery | 57 |
| Dr. George Zhengzhi Hill | Senior Consultant & Chief Medical Advisor | 74 |
| Mr. John P. Gargiulo M.B.A. | Chief Business Officer | 65 |
| Mr. Ming Fai Chung CPA | Company Secretary | 46 |
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for ASCLF, sourced from Markets Gazette.